HC Wainwright Reiterates Buy Rating on Dianthus Therapeutics, Sets $158 Target
HC Wainwright reiterated its Buy rating and $158 price target on Dianthus Therapeutics. The target implies 111.3% upside from the Oct. 14 close of $74.76.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.